Canopus BioPharma is also currently developing a range of novel antibiotics. These compounds are currently being screened for efficacy against a panel of bacteria including multi drug resistant tuberculosis (MDR TB) and MRSA.
CB2009 is a novel synthetic nonglucocorticoid 21-aminosteroid with anti-oxidant activity. Acting as a free-radical scavenger, CB2009 limits the extent of cell damage by inhibiting lipid peroxidation. In clinical trials, CB2009 has also demonstrated a good safety profile with few side-effects.
CB3900 is a non metabolised analogue of glucose which interferes with glycoprotein and glycolipid synthesis. This antimetabolite inhibits a number of enveloped RNA and DNA viruses. The relatively low toxicity in both experimental animal and human studies suggest the feasibility of employing this compound against bacterial infections.